Please login to the form below

Not currently logged in
Email:
Password:

Verastem promotes Robert Forrester to CEO

Takes over from Christoph Westphal who moves to executive chairman

US biotech Verastem has announced a change in personnel at the very top, with Robert Forrester to replace Christoph Westphal as CEO on July 1, while Westphal will become executive chairman.

Forrester currently serves as president and chief operating officer at the company, which specialises in developing drugs to treat cancer by the targeted killing of cancer stem cells.

His positions prior to joining Verastem includes senior roles at life sciences firms Forma Therapeutics, CombinatoR and Coley. He has experience in other industries too, serving at investment banks BZW and UBS, and at investment group MeesPierson.

“Robert's experience and expertise are perfectly suited to advancing our company through clinical development and creating value for shareholders, making this an ideal time to effect this transition,” said Westphal, who also confirmed his own future interest in the company.

“As the largest investor, and with an active 10b5-1 buying plan, Verastem will remain my principal focus. Robert and I will continue to work closely with the board of directors to implement our strategy.”

11th June 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics